Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1016

1.

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Tai YT, Anderson KC.

Expert Opin Biol Ther. 2019 Jul 11:1-14. doi: 10.1080/14712598.2019.1641196. [Epub ahead of print]

PMID:
31277554
2.

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

Adamia S, Abiatari I, Amin SB, Fulciniti M, Minvielle S, Li C, Moreau P, Avet-Loiseau H, Munshi NC, Anderson KC.

Leukemia. 2019 Jun 10. doi: 10.1038/s41375-019-0498-5. [Epub ahead of print]

PMID:
31182781
3.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
4.

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.

Ho M, Chen T, Liu J, Dowling P, Hideshima T, Zhang L, Morelli E, Camci-Unal G, Wu X, Tai YT, Wen K, Samur M, Schlossman RL, Mazitschek R, Kavanagh EL, Lindsay S, Harada T, McCann A, Anderson KC, O'Gorman P, Bianchi G.

Leukemia. 2019 May 29. doi: 10.1038/s41375-019-0493-x. [Epub ahead of print]

PMID:
31142847
5.

Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.

Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Clin Cancer Res. 2019 May 1;25(9):2938. doi: 10.1158/1078-0432.CCR-19-0959. No abstract available.

PMID:
31043386
6.

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.

Song Y, Park PMC, Wu L, Ray A, Picaud S, Li D, Wimalasena VK, Du T, Filippakopoulos P, Anderson KC, Qi J, Chauhan D.

Leukemia. 2019 Apr 8. doi: 10.1038/s41375-019-0467-z. [Epub ahead of print]

PMID:
30962579
7.

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

Jagannath S, Heffner LT Jr, Ailawadhi S, Munshi NC, Zimmerman TM, Rosenblatt J, Lonial S, Chanan-Khan A, Ruehle M, Rharbaoui F, Haeder T, Wartenberg-Demand A, Anderson KC.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):372-380. doi: 10.1016/j.clml.2019.02.006. Epub 2019 Feb 21.

PMID:
30930134
8.

Deciphering the chronology of copy number alterations in Multiple Myeloma.

Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK.

Blood Cancer J. 2019 Mar 26;9(4):39. doi: 10.1038/s41408-019-0199-3.

9.
10.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2019 Apr;33(4):1058-1059. doi: 10.1038/s41375-019-0410-3.

PMID:
30842604
11.

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, Dimopoulos MA.

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6. No abstract available.

PMID:
30773670
12.

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

Cho SF, Anderson KC, Tai YT.

Ann Transl Med. 2018 Dec;6(Suppl 2):S93. doi: 10.21037/atm.2018.11.14. No abstract available.

13.

Body Composition Is Associated With Physical Performance in Individuals With Knee Osteoarthritis.

Davis HC, Blue MNM, Hirsch KR, Luc-Harkey BA, Anderson KC, Smith-Ryan AE, Pietrosimone B.

J Clin Rheumatol. 2019 Feb 1. doi: 10.1097/RHU.0000000000000967. [Epub ahead of print]

PMID:
30724754
14.

The NIH Blueprint for Neuroscience Research Seeks Community Input on Future Neuroscience Investments.

Mott MC, Austin CP, Bianchi DW, Cashion AK, Gordon JA, Heemskerk JE, Hodes RJ, Koob GF, Riley WT, Sieving PA, Shurtleff D, Somerman MJ, Volkow ND, Anderson KC, Owens DF, Koroshetz WJ.

J Neurosci. 2019 Jan 30;39(5):774-775. doi: 10.1523/JNEUROSCI.2742-18.2018. No abstract available.

PMID:
30700523
15.

Contribution of Inhibition of Protein Catabolism in Myeloma.

Bianchi G, Anderson KC.

Cancer J. 2019 Jan/Feb;25(1):11-18. doi: 10.1097/PPO.0000000000000349.

PMID:
30694855
16.

Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis.

Guang MHZ, Kavanagh EL, Dunne LP, Dowling P, Zhang L, Lindsay S, Bazou D, Goh CY, Hanley C, Bianchi G, Anderson KC, O'Gorman P, McCann A.

Cancers (Basel). 2019 Jan 9;11(1). pii: E66. doi: 10.3390/cancers11010066. Review.

17.

PRMT5 inhibitors on the (myeloma) road.

Gulla A, Hideshima T, Anderson KC.

Oncotarget. 2018 Nov 30;9(94):36646-36647. doi: 10.18632/oncotarget.26392. eCollection 2018 Nov 30. No abstract available.

18.

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.

Fulciniti M, Lin CY, Samur MK, Lopez MA, Singh I, Lawlor MA, Szalat RE, Ott CJ, Avet-Loiseau H, Anderson KC, Young RA, Bradner JE, Munshi NC.

Cell Rep. 2018 Dec 26;25(13):3693-3705.e6. doi: 10.1016/j.celrep.2018.12.016.

19.

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.

Wildes TM, Anderson KC.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):88-96. doi: 10.1182/asheducation-2018.1.88. Review.

PMID:
30504296
20.

The power of proteasome inhibition in multiple myeloma.

Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG.

Expert Rev Proteomics. 2018 Dec;15(12):1033-1052. doi: 10.1080/14789450.2018.1543595. Epub 2018 Nov 14. Review.

PMID:
30427223
21.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC.

Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0. Review.

22.

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP.

Blood Adv. 2018 Nov 13;2(21):2937-2946. doi: 10.1182/bloodadvances.2018022962.

23.

The effects of nutrient timing on training adaptations in resistance-trained females.

Pihoker AA, Peterjohn AM, Trexler ET, Hirsch KR, Blue MNM, Anderson KC, Ryan ED, Smith-Ryan AE.

J Sci Med Sport. 2019 Apr;22(4):472-477. doi: 10.1016/j.jsams.2018.09.236. Epub 2018 Oct 10.

PMID:
30366741
24.

Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.

Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen CT, Wetzel L, Chen R, Dimasi N, Tai YT, Anderson KC, Herbst R, Howard PW, Hurt EM, Tice DA.

Leukemia. 2019 Mar;33(3):766-771. doi: 10.1038/s41375-018-0278-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315237
25.

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.

Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin M, Reynolds C, Shain KH, Zackon I, Stampleman L, Henrick P, Rivotto B, Hornburg KTV, Dumke HJ, Chuma S, Savell A, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM.

Clin Cancer Res. 2019 Jan 15;25(2):478-486. doi: 10.1158/1078-0432.CCR-18-1325. Epub 2018 Oct 2.

PMID:
30279233
26.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.

Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.

PMID:
30249784
27.

A transcriptomic investigation of appetite-regulation and digestive processes in giant grouper Epinephelus lanceolatus during early larval development.

Anderson KC, Knuckey R, Cánepa M, Elizur A.

J Fish Biol. 2018 Oct;93(4):694-710. doi: 10.1111/jfb.13798.

PMID:
30232812
28.

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.

Leukemia. 2018 Oct;32(10):2305. doi: 10.1038/s41375-018-0235-5.

PMID:
30218008
29.

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.

Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter Z, Anderson KC, Treon SP, Munshi NC, Fulciniti M.

Clin Cancer Res. 2019 Jan 1;25(1):369-377. doi: 10.1158/1078-0432.CCR-18-1776. Epub 2018 Sep 11.

PMID:
30206161
30.

The biological significance of histone modifiers in multiple myeloma: clinical applications.

Ohguchi H, Hideshima T, Anderson KC.

Blood Cancer J. 2018 Aug 22;8(9):83. doi: 10.1038/s41408-018-0119-y. Review.

31.

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.

Gandolfi S, Vekstein C, Laubach JP, O'Brien A, Masone K, Munshi NC, Anderson KC, Richardson PG.

Clin Adv Hematol Oncol. 2018 Aug;16(8):564-574. Review.

PMID:
30148829
32.

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.

Tai YT, Cho SF, Anderson KC.

Front Immunol. 2018 Aug 10;9:1822. doi: 10.3389/fimmu.2018.01822. eCollection 2018. Review.

33.

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Cho SF, Anderson KC, Tai YT.

Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018. Review.

34.

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.

Tai YT, Lin L, Xing L, Cho SF, Yu T, Acharya C, Wen K, Hsieh PA, Dulos J, van Elsas A, Munshi N, Richardson P, Anderson KC.

Leukemia. 2019 Feb;33(2):426-438. doi: 10.1038/s41375-018-0242-6. Epub 2018 Aug 22.

35.

SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.

Kinneer K, Meekin J, Tiberghien AC, Tai YT, Phipps S, Kiefer CM, Rebelatto MC, Dimasi N, Moriarty A, Papadopoulos KP, Sridhar S, Gregson SJ, Wick MJ, Masterson L, Anderson KC, Herbst R, Howard PW, Tice DA.

Clin Cancer Res. 2018 Dec 15;24(24):6570-6582. doi: 10.1158/1078-0432.CCR-18-1300. Epub 2018 Aug 21.

PMID:
30131388
36.

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.

Liu J, Song T, Zhou W, Xing L, Wang S, Ho M, Peng Z, Tai YT, Hideshima T, Anderson KC, Cang Y.

Leukemia. 2019 Jan;33(1):171-180. doi: 10.1038/s41375-018-0205-y. Epub 2018 Jul 19.

37.

Promise of Immune Therapies in Multiple Myeloma.

Anderson KC.

J Oncol Pract. 2018 Jul;14(7):411-413. doi: 10.1200/JOP.18.00311. No abstract available.

38.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G.

Leukemia. 2019 Jan;33(1):159-170. doi: 10.1038/s41375-018-0196-8. Epub 2018 Jul 2.

39.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ.

Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8. Erratum in: Blood. 2018 Sep 27;132(13):1461.

40.

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG.

Br J Haematol. 2018 Aug;182(4):495-503. doi: 10.1111/bjh.15384. Epub 2018 May 29.

41.

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, O'Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson KC, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC.

Leukemia. 2018 Dec;32(12):2604-2616. doi: 10.1038/s41375-018-0037-9. Epub 2018 May 22.

42.

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.

Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, Szalat R, Shammas M, Magrangeas F, Tai YT, Auclair D, Keats J, Richardson P, Attal M, Moreau P, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC.

Leukemia. 2018 Dec;32(12):2626-2635. doi: 10.1038/s41375-018-0116-y. Epub 2018 Mar 29.

43.

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.

Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, Yee AJ, O'Donnell EK, Tai YT, Richardson PG, Bianchi G, Laubach JP, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi NC, Anderson KC, Knoechel B, Lohr JG.

Leukemia. 2018 Aug;32(8):1838-1841. doi: 10.1038/s41375-018-0115-z. Epub 2018 Mar 27. No abstract available.

PMID:
29749395
44.

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.

Varga C, Laubach JP, Anderson KC, Richardson PG.

Br J Haematol. 2018 May;181(4):433-446. doi: 10.1111/bjh.15116. Epub 2018 May 10. Review.

PMID:
29748955
45.

Meaningful changes in end-of-life care among patients with myeloma.

Odejide OO, Li L, Cronin AM, Murillo A, Richardson PG, Anderson KC, Abel GA.

Haematologica. 2018 Aug;103(8):1380-1389. doi: 10.3324/haematol.2018.187609. Epub 2018 May 10.

46.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS.

Br J Haematol. 2018 Jul;182(2):222-230. doi: 10.1111/bjh.15261. Epub 2018 May 8.

47.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM.

Cancer Res. 2018 May 15;78(10):2747-2759. doi: 10.1158/0008-5472.CAN-17-1900. Epub 2018 Mar 20.

48.

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.

Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, Munshi NC, Anderson KC.

Leukemia. 2018 Sep;32(9):1932-1947. doi: 10.1038/s41375-018-0062-8. Epub 2018 Feb 22.

49.

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

Breitkreutz I, Podar K, Figueroa-Vazquez V, Wilhelm S, Hayden PJ, Anderson KC, Raab MS.

Ann Hematol. 2018 May;97(5):839-849. doi: 10.1007/s00277-018-3237-5. Epub 2018 Jan 23.

PMID:
29359239
50.

Targeting CD38 alleviates tumor-induced immunosuppression.

Tai YT, Anderson KC.

Oncotarget. 2017 Dec 26;8(68):112166-112167. doi: 10.18632/oncotarget.22992. eCollection 2017 Dec 22. No abstract available.

Supplemental Content

Loading ...
Support Center